Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 5/20 | 0.31 |
| ▸ | BRAF | P15056 | 5/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138966 | 0.91 | TTK (0.42) | TTKIRAK4CNR2CNR1RAF1 | |
| SCHEMBL104885 | 0.88 | IRAK4 (0.33) | TTKIRAK4CNR2CNR1HTR4 | |
| SCHEMBL104784 | 0.87 | GPR119 (0.33) | IRAK4CNR2CNR1RAF1BRAF | |
| SCHEMBL105318 | 0.83 | TTK (0.37) | TTKIRAK4 | |
| SCHEMBL104889 | 0.82 | TTK (0.42) | TTKCNR2CNR1VNN1 | |
| SCHEMBL105028 | 0.81 | OPRM1 (0.30) | — | |
| SCHEMBL16018374 | 0.78 | L3MBTL1 (0.38) | CNR2CNR1 | |
| SCHEMBL104135 | 0.77 | TTK (0.68) | TTK | |
| SCHEMBL139379 | 0.76 | MAPK14 (0.37) | TTKIRAK4HTR4RAF1BRAF | |
| SCHEMBL105076 | 0.75 | TTK (0.34) | TTKCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TTK 6/4885IRAK4 1082/4885CNR2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.